65 result(s) have been found!
| Accession | Name | Sequence | Source/Organism | Mechanism | Assay Type | Cell Line | Cancer Type | Activity |
|---|---|---|---|---|---|---|---|---|
| dbacp01440 | BAA-1 | NA | Bovine lactoferrin (Lf-B) | Destabilizing the cell membrane | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 8.1 µg/ml |
| dbacp01441 | BAA-2 | NA | Bovine lactoferrin (Lf-B) | Apoptosis inducing | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 3.8 µg/ml |
| dbacp03375 | IL-4Rα-lytic hybrid peptide | KQLIRFLKRLDRNGGGKLlLKlLkkLLKlLKKK | Bovine lactoferrin (Lf-B) | Induction of apoptosis | WST-1 assay | KB | Oral cancer | IC50 : 13.2 µMol/L |
| dbacp03529 | KW5 | KAAKKAAKAAKKAAKAAKKAA | Bovine lactoferrin (Lf-B) | Through interactions with the plasma membrane | MTT/MTS assay | FEMX | Skin cancer | IC50 : 30 ± 3 µM |
| dbacp03549 | L1 | PEWFKCRRWQWRMKKLGA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : > 404 µM |
| dbacp03550 | L1 | PEWFKCRRWQWRMKKLGA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : > 404 µM |
| dbacp03551 | L1 | PEWFKCRRWQWRMKKLGA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : > 404 µM |
| dbacp03552 | L10 | PAARKAFRWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 24 µM |
| dbacp03553 | L10 | PAARKAFRWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 20 µM |
| dbacp03554 | L10 | PAARKAFRWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 35 µM |
| dbacp03555 | L11 | PAARKAARWAWRMLKKGA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 116 µM |
| dbacp03556 | L11 | PAARKAARWAWRMLKKGA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 75 µM |
| dbacp03557 | L11 | PAARKAARWAWRMLKKGA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 248 µM |
| dbacp03558 | L12 | PAWRKAFRWAKRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 7.9 µM |
| dbacp03559 | L12 | PAWRKAFRWAKRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 10 µM |
| dbacp03560 | L12 | PAWRKAFRWAKRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 25 µM |
| dbacp03561 | L13 | PAWRKAFRKAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 14 µM |
| dbacp03562 | L13 | PAWRKAFRKAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 12 µM |
| dbacp03563 | L13 | PAWRKAFRKAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 29 µM |
| dbacp03564 | L14 | PAWRKARRWAWRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 125 µM |
| dbacp03565 | L14 | PAWRKARRWAWRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 141 µM |
| dbacp03566 | L14 | PAWRKARRWAWRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 423 µM |
| dbacp03567 | L15 | PAWRKARRWARRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 87 µM |
| dbacp03568 | L15 | PAWRKARRWARRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 92 µM |
| dbacp03569 | L15 | PAWRKARRWARRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 178 µM |
| dbacp03586 | L2 | PAWFKARRWAWRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 144 µM |
| dbacp03587 | L2 | PAWFKARRWAWRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : >254 µM |
| dbacp03588 | L2 | PAWFKARRWAWRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : >440 µM |
| dbacp03597 | L3 | PAWRKAFRWAWRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 32 µM |
| dbacp03598 | L3 | PAWRKAFRWAWRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 18 µM |
| dbacp03599 | L3 | PAWRKAFRWAWRMKKLAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 141 µM |
| dbacp03604 | L4 | PAWFKARRWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 31 µM |
| dbacp03605 | L4 | PAWFKARRWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 16 µM |
| dbacp03606 | L4 | PAWFKARRWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 57 µM |
| dbacp03607 | L5 | PAWRKAFRWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 6.6 µM |
| dbacp03608 | L5 | PAWRKAFRWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 8 µM |
| dbacp03609 | L5 | PAWRKAFRWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 14 µM |
| dbacp03610 | L6 | PAWRKAFRWAARMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 11 µM |
| dbacp03611 | L6 | PAWRKAFRWAARMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 12 µM |
| dbacp03612 | L6 | PAWRKAFRWAARMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 15 µM |
| dbacp03629 | L7 | PAWRKAFRAAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 16 µM |
| dbacp03630 | L7 | PAWRKAFRAAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 11 µM |
| dbacp03631 | L7 | PAWRKAFRAAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 16 µM |
| dbacp03632 | L8 | PAWAKAFRAAARMKLKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 110 µM |
| dbacp03633 | L8 | PAWAKAFRAAARMKLKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 : 87 µM |
| dbacp03634 | L8 | PAWAKAFRAAARMKLKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 180 µM |
| dbacp03635 | L9 | PAWRKAARWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | Meth A | Skin cancer | IC50 : 35 µM |
| dbacp03636 | L9 | PAWRKAARWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | MT-1 | Breast cancer | IC50 :32 µM |
| dbacp03637 | L9 | PAWRKAARWAWRMLKKAA | Lactoferrin | Cell membrane disintegration | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 52 µM |
| dbacp03730 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | HT-29 | Colon cancer | IC50 : > 160 µM |
| dbacp03731 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | MT-1 | Breast cancer | IC50 : > 160 µM |
| dbacp03732 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | Kelly | Brain tumor | IC50 : 141 ± 3 µM |
| dbacp03733 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | FEMX | Skin cancer | IC50 : 40 ± 7 µM |
| dbacp03734 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | HT-29 | Colon cancer | IC50 : 148 ± 8 µM |
| dbacp03735 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | KMS-5 | Skin cancer | IC50 : 38 µM |
| dbacp03736 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | U-266 | Lymphoma cancer | IC50 : 55 µM |
| dbacp03737 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | KMM-1 | Skin cancer | IC50 : 57 µM |
| dbacp03738 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | Sudhl-4 | Skin cancer | IC50 : 16 µM |
| dbacp03739 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | Raji | Lymphoma cancer | IC50 : 13 µM |
| dbacp03740 | LfcinB | FKCRRWQWRMKK | Bovine lactoferrin (Lf-B) | Cell membrane disintegration; Regulation of immune response; Apoptosis | MTT/MTS assay | Ramos | Lymphoma cancer | IC50 : 10 µM |
| dbacp04349 | Lytic | KLlLKlLkkLLKlLKKK | Bovine lactoferrin (Lf-B) | Induction of apoptosis | WST-1 assay | KB | Oral cancer | IC50 : 37.4 µMol/L |
| dbacp04701 | mPep1 | RKAFRWAWRMLKKAAPSITCVR | Bovine lactoferrin (Lf-B) | Necrotic cell death by destroying cellular membrane structure; Apoptotic cell death | MTT/MTS assay | HL-60 | Skin cancer | IC50 :8 µM |
| dbacp05038 | P18 | KWKLFKKIPKFLHLAKKF | Bovine lactoferrin (Lf-B) | Necrosis; Cell membrane rupture | MTT/MTS assay | M14 | Skin cancer | 92.2 ± 1.02% cell viability at 10 µM |
| dbacp05245 | pep1 | FKCRRWQWRMKKLGAPSITCVR | Bovine lactoferrin (Lf-B) | Activating an apoptosis-inducing pathway | MTT/MTS assay | HL-60 | Prostate cancer | IC50 :77 µM |
| dbacp06170 | SVS-1 | KVKVKVKVpPTKVKVKVK | Bovine lactoferrin (Lf-B) | Disruption of cell membranes | MTT/MTS assay | KB | Oral cancer | Not found |